Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 231

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis

Open access
Jarius, Sven, Aktas, Orhan, Ayzenberg, Ilya, Bellmann-Strobl, Judith, Berthele, Achim, Giglhuber, Katrin, Häußler, Vivien, Havla, Joachim, Hellwig, Kerstin, Hümmert, Martin W., Kleiter, Ingo, Klotz, Luisa, Krumbholz, Markus, Kümpfel, Tania, Paul, Friedemann, Ringelstein, Marius, Ruprecht, Klemens, Senel, Makbule, Stellmann, Jan-Patrick, Bergh, Florian Then, Tumani, Hayrettin, Wildemann, Brigitte, Trebst, Corinna, Neuromyelitis Optica Study Group (NEMOS) · 2023 · Journal of Neurology

Abstract

The term ‘neuromyelitis optica spectrum disorders’ (NMOSD) is used as an umbrella term that refers to aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica (NMO) and its formes frustes and to a number of closely related clinical syndromes without AQP4-IgG. NMOSD were originally considered subvariants of multiple sclerosis (MS) but are now widely recognized as disorders in their own right that are distinct from MS with regard to immunopathogenesis, clinical presentation, optimum treatment, and prognosis. In part 1 of this two-part article series, which ties in with our 2014 recommendations, the neuromyelitis optica study group (NEMOS) gives updated recommendations on the diagnosis and differential diagnosis of NMOSD. A key focus is on differentiating NMOSD from MS and from myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD), which shares significant similarity with NMOSD with regard to clinical and, partly, radiological presentation, but is a pathogenetically distinct disease. In part 2, we provide updated recommendations on the treatment of NMOSD, covering all newly approved drugs as well as established treatment options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00415-023-11634-0

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 231

Metadata

Authors
Jarius, S., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Berthele, A., Giglhuber, K., Häußler, V., Havla, J., Hellwig, K., Hümmert, M. W., Kleiter, I., Klotz, L., Krumbholz, M., Kümpfel, T., Paul, F., Ringelstein, M., Ruprecht, K., Senel, M., Stellmann, J.-P., Bergh, F. T., Tumani, H., Wildemann, B., Trebst, C., & Neuromyelitis Optica Study Group (NEMOS)
Venue
Journal of Neurology
Published
2023-04-06
Volume
270
Issue
7
Pages
3341-3368
ISSN
  • 0012-1037 (ISSN-L)
  • 0340-5354
  • 1432-1459
OpenAlex
W4362658161
Cited by
231
References
11
FWCI
38.20
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. https://app.cochat.ai/papers/10.1007/s00415-023-11634-0
The paper
Jarius, S., Aktas, O., Ayzenberg, I., Bellmann-Strobl, J., Berthele, A., Giglhuber, K., Häußler, V., Havla, J., Hellwig, K., Hümmert, M. W., Kleiter, I., Klotz, L., Krumbholz, M., Kümpfel, T., Paul, F., Ringelstein, M., Ruprecht, K., Senel, M., Stellmann, J.-P., . . . Neuromyelitis Optica Study Group (NEMOS). (2023). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal of Neurology. https://doi.org/10.1007/s00415-023-11634-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.